PCV88 THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELANDBackground: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal ...
Cost-Effectiveness Analysis Of Ambrisentan Versus Bosentan In The Treatment Of Patients With Pulmonary Arterial Hypertension Functional Class IIIMaternal MortalityHealth systemsSystematic ReviewResearch EvidenceBackground: The impact of efforts by healthcare organizations to enhance the use of evidence to ...